Trinity Biotech (TRIB) Non-Current Deferred Tax Liability (2009 - 2025)

Trinity Biotech has disclosed Non-Current Deferred Tax Liability across 17 years of filings, most recently posting $4.7 million for Q4 2025.

• Non-Current Deferred Tax Liability for Q4 2025 came in at $4.7 million, up 2.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.7 million (up 2.32% YoY), and the FY2025 annual result was $4.7 million, up 2.32% from the prior year.
• Non-Current Deferred Tax Liability came in at $4.7 million for Q4 2025 at Trinity Biotech, up from $4.6 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $5.4 million in Q2 2022 to a low of $195000.0 in Q4 2023.
• The 5-year median for Non-Current Deferred Tax Liability is $4.6 million (2024), against an average of $4.0 million.
• Across the five-year window, Non-Current Deferred Tax Liability sank 96.14% in 2023 and jumped 2238.97% in 2024, its largest moves.
• Trinity Biotech's Non-Current Deferred Tax Liability stood at $4.9 million in 2021, then increased by 4.12% to $5.1 million in 2022, then tumbled by 96.14% to $195000.0 in 2023, then surged by 2238.97% to $4.6 million in 2024, then rose by 2.32% to $4.7 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $4.7 million (Q4 2025), $4.6 million (Q2 2025), and $4.6 million (Q4 2024), per Business Quant data.